This website is for informational purposes only and does not constitute medical advice. Read disclaimer
Ziconotide
A synthetic peptide derived from cone snail venom that selectively blocks N-type calcium channels, delivered intrathecally for the management of severe chronic pain refractory to other therapies.
Overview
Ziconotide is a synthetic 25-amino acid peptide that is the pharmaceutical form of omega-conotoxin MVIIA, a neurotoxin originally isolated from the venom of the marine cone snail Conus magus. Approved by the FDA in 2004 and marketed as Prialt, ziconotide represents a unique analgesic mechanism — it is a highly selective and potent blocker of N-type voltage-gated calcium channels (Cav2.2) located on primary afferent nociceptive nerve terminals in the spinal cord dorsal horn.
N-type calcium channels play a critical role in the transmission of pain signals. When a pain signal reaches the spinal cord, calcium influx through these channels triggers the release of neurotransmitters (including substance P and glutamate) that relay the pain signal to higher brain centers. By blocking N-type calcium channels, ziconotide prevents this neurotransmitter release, effectively interrupting the pain signal at the spinal level without activating opioid receptors. This mechanism makes it the first non-opioid intrathecal analgesic.
Ziconotide must be delivered intrathecally (directly into the cerebrospinal fluid) via an implanted programmable infusion pump or external microinfusion device because it cannot cross the blood-brain barrier and has no analgesic effect when administered systemically. The drug is indicated for the management of severe chronic pain in patients who are intolerant of or refractory to other analgesic therapies, including intrathecal morphine.
Clinical trials demonstrated significant pain reduction in patients with severe chronic pain from cancer and non-cancer etiologies. However, ziconotide has a narrow therapeutic window, and dose titration must be very slow (increases no more frequently than 2-3 times per week) to avoid serious neuropsychiatric adverse effects, which can include cognitive impairment, psychosis, hallucinations, and suicidal ideation.